Novonorm 2 mg (Repaglinide) – Product Overview

Novonorm 2 mg is a prescription oral antidiabetic medication that contains repaglinide as the active ingredient. Manufactured by Novo Nordisk India, each strip contains 15 tablets, each delivering a 2 mg dose of repaglinide. The product is indicated for the management of type 2 diabetes mellitus when lifestyle modification alone is insufficient to achieve glycemic control.

What is Novonorm 2 mg?

Repaglinide belongs to the class of meglitinides, a group of drugs that lower blood glucose by stimulating insulin release from pancreatic beta‑cells in a glucose‑dependent manner. Unlike sulfonylureas, repaglinide’s action is rapid and short‑lived, making it particularly useful for controlling post‑prandial glucose spikes. The 2 mg strength is the most commonly prescribed dose for patients who require modest glucose‑lowering effect or who are transitioning from lower doses.

Uses and Benefits

The primary use of Novonorm 2 mg is to improve glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated that repaglinide can reduce HbA1c by approximately 0.5–1.0 % when used as monotherapy or in combination with metformin or other oral agents. Its rapid onset (within 15–30 minutes) and short duration (about 4–6 hours) allow flexible dosing before meals, which can be advantageous for patients with irregular eating patterns.

Additional benefits include:

• Reduced risk of hypoglycemia compared with longer‑acting sulfonylureas when used at recommended doses.
• Weight‑neutral profile; many patients experience little or no weight gain.
• Compatibility with renal impairment when dose‑adjusted appropriately.

How It Works

Repaglinide binds to the ATP‑sensitive potassium channel on pancreatic beta‑cells, leading to closure of the channel and influx of calcium. This triggers insulin secretion in a glucose‑dependent fashion. Because the drug’s effect is directly linked to the glucose concentration, the risk of excessive insulin release—and thus hypoglycemia—is minimized when carbohydrate intake is moderate.

Pharmacokinetic data indicate that repaglinide is rapidly absorbed, reaches peak plasma concentrations within one hour, and is primarily metabolized by the liver via the cytochrome P450 2C8 enzyme. Approximately 80 % of the administered dose is eliminated through hepatic metabolism, with a half‑life of about 1.5 hours.

Clinical Efficacy and Safety

Multiple randomized controlled trials have assessed repaglinide in patients with type 2 diabetes. In a 24‑week study, repaglinide reduced fasting plasma glucose by 15–20 mg/dL versus placebo and lowered HbA1c by about 0.6 %. Adverse events were generally mild, most commonly transient hypoglycemia and upper respiratory infections. Long‑term follow‑up to 5 years showed no increase in cardiovascular mortality, supporting its use as an adjunct to lifestyle modification. For more detailed trial data, see clinical trials.

Dosage Guidelines

Novonorm 2 mg tablets are typically taken before each main meal (usually three times daily). The exact dose is individualized based on baseline glycemic control, renal function, and concomitant antidiabetic therapy.

Special populations and renal considerations: Patients with mild to moderate renal impairment (eGFR 30–60 mL/min/1.73 m²) do not require routine dose adjustment, but close glucose monitoring is recommended. In those with severe renal dysfunction (eGFR <30 mL/min/1.73 m²), the maximum daily dose should not exceed 2 mg, and dosing frequency may be reduced to twice daily. Hepatic impairment: For patients with moderate hepatic disease (Child‑Pugh B), the starting dose should be limited to 0.5 mg before each main meal, with careful titration. Severe hepatic disease (Child‑Pugh C) contraindicates use of repaglinide due to reduced metabolic clearance and increased risk of accumulation.

General dosing recommendations include:

• Initial dose: 0.5 mg before each meal (or 1 mg if prescribed by a physician).
• Titration: Increase by 0.5 mg increments every 1–2 weeks as needed, up to a maximum of 4 mg per day (often given as 2 mg before each meal).
• Adjustment in patients with hepatic impairment: Reduce the dose by half due to decreased metabolic clearance.
• Renal impairment: No routine dose adjustment is required for mild to moderate renal dysfunction; however, in severe renal impairment the dose should be limited to 1 mg before each meal.

Patients should be instructed to skip a dose if they miss a meal or if their blood glucose is already low. Regular monitoring of blood glucose is recommended to avoid hypoglycemic episodes.

Side Effects

Like all medications, Novonorm 2 mg may cause adverse effects. The most frequently reported side effects include:

• Hypoglycemia (low blood sugar), especially when combined with other glucose‑lowering agents.
• Upper respiratory tract infections.
• Gastrointestinal discomfort such as nausea or diarrhea.
• Weight gain in some patients.

Less common but clinically significant adverse reactions are:

• Hepatic enzyme elevations; periodic liver function tests are advisable.
• Allergic skin reactions.

Patients should discontinue the medication and seek medical attention if they experience severe hypoglycemia, persistent liver problems, or signs of an allergic reaction (rash, itching, swelling).

Management of Hypoglycemia

If hypoglycemic symptoms occur, patients should immediately consume a fast‑acting carbohydrate such as glucose tablets or a sugary beverage. The recommended initial treatment is 15 g of glucose, followed by re‑measurement of blood glucose after 15 minutes. If glucose remains <70 mg/dL, repeat the carbohydrate intake. Severe hypoglycemia characterized by loss of consciousness or inability to swallow requires emergency glucagon administration and medical attention. Patients should be educated on recognizing early signs of low blood sugar and on the proper steps to correct it.

Warnings and Precautions

Novonorm 2 mg is contraindicated in patients with known hypersensitivity to repaglinide or any component of the formulation. It should not be used in type 1 diabetes or in patients with diabetic ketoacidosis. Caution is advised in:

• Patients with moderate to severe hepatic impairment (Child‑Pugh B or C).
• Those with adrenal or pituitary insufficiency, which may predispose to hypoglycemia.
• Pregnant or breastfeeding women; the drug should only be used if the benefits outweigh the risks, and only under medical supervision.

Pregnancy, lactation, and pediatric use: Novonorm 2 mg is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus but there are no adequate human studies. Pregnant women should use the medication only if the benefits outweigh the potential risks and under close medical supervision. It is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.

Drug Interactions

Drug interactions can alter repaglinide levels. Strong inhibitors of CYP2C8 (e.g., gemfibrozil) may increase exposure, while inducers (e.g., rifampicin) may decrease it. Concomitant use with other antidiabetic agents requires careful glucose monitoring.

Food and beverage considerations: Repaglinide’s absorption is not significantly affected by food, but administration with a high‑carbohydrate meal may increase the magnitude of insulin secretion, potentially raising the risk of post‑prandial hypoglycemia. Patients are advised to take the tablet within 30 minutes before the main meal to align peak drug action with glucose intake. Alcohol consumption can potentiate the hypoglycemic effect and should be used cautiously.

Frequently Asked Questions

1. Can Novonorm 2 mg be taken with meals that are skipped? No. The medication should only be taken before a meal that contains carbohydrates. Skipping a meal or eating a low‑carbohydrate meal reduces the risk of hypoglycemia.
2. How long does it take to see a reduction in HbA1c? Clinical studies show a modest decrease in HbA1c after 12–24 weeks of consistent use, when combined with diet and exercise.
3. Is Novonorm 2 mg safe for elderly patients? Elderly patients may be more sensitive to hypoglycemia; clinicians typically start with a lower dose (0.5 mg) and titrate slowly.
4. Do I need to adjust my insulin dose while using Novonorm 2 mg? If insulin is also prescribed, dose reductions are often necessary to avoid hypoglycemia; always consult a healthcare professional before making changes.
5. Where can I find more detailed prescribing information? The official prescribing information is available on the FDA website and on Drugs.com; additional data can be accessed through PubMed for peer‑reviewed studies.

For additional authoritative resources, refer to the MedlinePlus entry on type 2 diabetes and the PubMed database for peer‑reviewed studies on repaglinide.

Overall, Novonorm 2 mg offers a valuable therapeutic option for patients seeking flexible, meal‑time glucose control with a low‑risk profile for hypoglycemia when used as directed. Always follow the prescribing physician’s instructions and maintain regular follow‑up to ensure optimal diabetes management.

Related Products

• Okamet 500 Mg (Metformin)
• Novofine 31G Needle (Device)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)
• Glycomet-GP 2 Forte (Metformin/Glimepiride)
• Glycomet-GP 1 Forte (Metformin/Glimepiride)
• Glimepiride 4 mg (Generic)